Updated clinical practice guidelines for the prevention and treatment of mucositis

Abstract

The opinions or views expressed in this professional review are those of the authors and do not necessarily reflect the opinions or recommendations of the publisher or the companies that provided grants toward this process. This article is being published with the full knowledge and consent of the authors. This article may discuss pharmaceutical products and/or uses of products that have not been approved by the U.S. Food and Drug Administration or other regulatory authorities outside of the United States. For approved product information, consult the manufacturer's prescribing information or the applicable regulatory authority. Dosages, indications, and methods of use for compounds that are referred to in this article may be derived from the professional literature or other sources. In vitro and animal data may not correlate with clinical results and do not demonstrate clinical safety or efficacy in humans.We acknowledge the assistance of Lee Ann Chastain in the preparation of this article.

Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients

“…To support evidence-based patient management and improve clinical outcomes, the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) has published evidence-based clinical practice guidelines for mucositis [48]. The purpose of this systematic review is to update the published MASCC/ISOO mucositis guidelines in relation to antimicrobial, mucosal coating, anesthetic, and analgesic agents [7].…”

N-acetyl cysteine for prevention of oral mucositis in hematopoietic SCT: a double-blind, randomized, placebo-controlled trial

“…32 Palifermin is currently the only drug approved by the US Food and Drug Administration for the prevention of OM in patients with hematologic malignancies who receive HDC. 33 In comparison with palifermin, NAC is relatively inexpensive and has no considerable interactions with antineoplastic drugs. [34][35][36][37] In our study, the overall duration of OM was also significantly shorter in the NAC group whereas in Jahangard-Rafsanjani et al 9 study, only the mean duration of severe OM (grade 3-4) was significantly lower in the intervention group (selenium).…”

The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT

“…Changes in guidelines to prevent or treat OM have recently been reviewed 31 and include the use of cryotherapy (ice-water or chips) during the infusion of high-dose melphalan; however, the authors also state: 'However, additional and sustained efforts will be required to gain a fuller understanding of the pathobiology, impact on overall patient status, optimal therapeutic strategies, and improved educational programs for health professionals, patients, and caregivers'.…”